An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients with Advanced Solid Malignancies

Trial Identifier:	D5330C00014
Sponsor:	AstraZeneca
NCTID::	NCT05469919
Start Date:	June 2022
Primary Completion Date:	August 2023
Study Completion Date:	December 2024
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
JP	Chuo-ku, JP, 104-0045

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.